Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]

Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results

Dr Olivier Casasnovas - CHU de Dijon, Dijon, France

Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results ( Dr Olivier Casasnovas - CHU de Dijon, Dijon, France )

Repurposing selective PDE5 inhibitors as anti-cancer agents

Dr Pan Pantziarka - Anticancer Fund, Brussels, Belgium

Repurposing selective PDE5 inhibitors as anti-cancer agents ( Dr Pan Pantziarka - Anticancer Fund, Brussels, Belgium )

First results of DREAM trial of frontline durvalumab for mesothelioma

Prof Anna Nowak - The University of Western Australia, Perth, Australia

First results of DREAM trial of frontline durvalumab for mesothelioma ( Prof Anna Nowak - The University of Western Australia, Perth, Australia )

Results from the phase I ICONIC trial

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Results from the phase I ICONIC trial ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

Phase II results of olaparib and abiraterone for mCRPC

Prof Noel Clarke - Salford Royal NHS Foundation Trust, Salford, UK

Phase II results of olaparib and abiraterone for mCRPC ( Prof Noel Clarke - Salford Royal NHS Foundation Trust, Salford, UK )

Design and interim safety analysis of GeparX trial

Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany

Design and interim safety analysis of GeparX trial ( Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany )

Subcutaneous daratumumab shows benefit in patients with relapsed or refractory...

Dr Ajai Chari - Mount Sinai Hospital, New York, USA

$Subcutaneous daratumumab shows benefit in patients with relapsed or refractory multiple myeloma ( Dr Ajai Chari - Mount Sinai Hospital, New York, USA )$

Avelumab in combinations for lung cancer and update from ALEX study

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Avelumab in combinations for lung cancer and update from ALEX study ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

Daratumumab in combination with carfilzomib and dexamethasone for relapsed...

Dr Ajai Chari - Mount Sinai Hospital, New York, USA

Daratumumab in combination with carfilzomib and dexamethasone for relapsed multiple myeloma ( Dr Ajai Chari - Mount Sinai Hospital, New York, USA )

Phase III results of PROSPECT study for metastatic, castration-resistant...

Dr James Gulley - Center for Cancer Research, Washington, USA

Phase III results of PROSPECT study for metastatic, castration-resistant prostate cancer ( Dr James Gulley - Center for Cancer Research, Washington, USA )

Pancreatic survival improved with trial chemotherapy regimen after surgery

Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Pancreatic survival improved with trial chemotherapy regimen after surgery ( Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

Aspirin combined with acid-reducing medicine offers moderate benefits in...

Prof Janusz Jankowski - Royal College of Surgeons in Ireland, Dublin, Republic...

Aspirin combined with acid-reducing medicine offers moderate benefits in patients with Barrett’s oesophagus ( Prof Janusz Jankowski - Royal College of Surgeons in Ireland, Dublin, Republic of Ireland )

More from ecancer